Novartis CEO: Trying to crack obesity market with another first-gen agent is ‘not a prudent approach’

No­var­tis doesn’t want to play the me-too game in obe­si­ty.

On Thurs­day, CEO Vas Narasimhan said that try­ing to com­pete in the multi­bil­lion-dol­lar obe­si­ty mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.